Floatz logo

16.ALPHA.-FLUOROESTRADIOL

Ductal Carcinoma in Situ - Category

University of Wisconsin, MadisonSmall moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Ductal Carcinoma in Situ - Category cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Zealand University Hospital
Phase 4BB
SUFENTANYL
Zealand University Hospital
Phase 4BB
TAMOXIFEN
Northwestern University
Phase 3BB
Metformin
M.D. Anderson Cancer Center
Phase 3BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

16.ALPHA.-FLUOROESTRADIOL is also rated in:

breast cancerDormant
B
Indicative ·
56 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CCC
Indicative ·
49 / 100
View asset →
breast cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →